Advertisement krishna chaitanya, Author at Pharmaceutical Business review

Advertisement

Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by krishna chaitanya

US FDA approves Sanofi’s new pediatric vaccine

The vaccine, called Vaxelis, is indicated to prevent diphtheria, tetanus, poliomyelitis, pertussis, hepatitis B and invasive disease due to Haemophilus influenzae type b. It has been approved for

Opiant and Sanofi sign licensing deal for drinabant

ACO is commonly associated with the ingestion of ‘edibles’ such as brownies, cookies and candies that contain large quantities of  D9-tetrahydrocannabinol (THC) and synthetic cannabinoids that are more

Lupin awards MALT1’s licensing rights to AbbVie

Indian pharmaceutical company Lupin has awarded the licensing rights of its Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) programme to AbbVie. The deal gives AbbVie exclusive global